SCHEMBL2556367

SCHEMBL2556367

Cc1nc(Br)ccc1OC1CCC(OC2CCN(C)CC2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.45
NOS3 P29474 1/20 0.38
NOS1 P29475 1/20 0.38
NOS2 P35228 1/20 0.38
HRH3 Q9Y5N1 2/20 0.37
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM5 P08912 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
FPR2 P25090 2/20 0.36
PROKR1 Q8TCW9 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
LRRK2 Q5S007 1/20 0.36
KDM4E B2RXH2 1/20 0.36
NPY1R P25929 1/20 0.36
NPY2R P49146 1/20 0.36
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
SCD O00767 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14634535 1.00 GPR119 (0.45) GPR119NOS3NOS1NOS2HRH3
SCHEMBL2557582 0.86 GPR119 (0.47) GPR119HRH3
SCHEMBL14634499 0.82 IKBKB (0.43) GPR119
SCHEMBL14634498 0.82 IKBKB (0.43) GPR119
SCHEMBL2554645 0.81 GPR119 (0.44) GPR119HRH3FPR2PROKR1SCD
SCHEMBL14634289 0.80 GPR119 (0.69) GPR119
SCHEMBL14634288 0.80 GPR119 (0.69) GPR119
SCHEMBL12282975 0.79 GPR119 (0.73) GPR119
SCHEMBL2553366 0.79 GPR119 (0.73) GPR119
SCHEMBL14634583 0.78 LRRK2 (0.41) GPR119HRH3CHRM2CHRM4CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2556056-A1 MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO Arena Pharmaceuticals, Inc. (US) 2013-02-13 EP disclosed
US-20130023494-A1 MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2013-01-24 US disclosed
WO-2011127051-A1 MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2011-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023494-A1 MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO GPR119, SLC5A2, SLC5A1 GPR119 1/4885NOS3 2637/4885NOS1 1678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.